The Role of the Asn40Asp Polymorphism of the Mu Opioid Receptor Gene (OPRM1) on Alcoholism Etiology and Treatment: A Critical Review

Alcoholism: Clinical and Experimental Research

Volumn 36, Issue 3, 2012, Pages 385-394

  Ray, Lara A ^a   Barr, Christina S ^b   Blendy, Julie A ^c   Oslin, David ^d   Goldman, David ^b   Anton, Raymond F ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcoholism; Asn40Asp; Genetics; Naltrexone; OPRM1; Pharmacogenetics

Indexed keywords

MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ALCOHOLISM; BEHAVIOR; BOLD SIGNAL; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NEUROIMAGING; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; CLINICAL TRIALS AS TOPIC; GENETIC ASSOCIATION STUDIES; HUMANS; NARCOTIC ANTAGONISTS; NEUROIMAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU;

ANIMALIA;

EID: 84855928475     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2011.01633.x     Document Type: Review

References (84)

1. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry65:135-144.
2. Arias A, Feinn R, Kranzler HR (2006) Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend83:262-268.
3. Baros AM, Latham PK, Anton RF (2008) Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist?Alcohol Clin Exp Res32:771-776.
4. Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M (2010) Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry67:78-80.
5. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M (2007) Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry64:369-376.
6. Barr CS, Schwandt ML, Lindell SG, Higley JD, Maestripieri D, Goldman D, Suomi SJ, Heilig M (2008) Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc Natl Acad Sci USA105:5277-5281.
7. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M (2005) Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology30:417-422.
8. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem276:3130-3137.
9. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry2:490-494.
10. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem89:553-560.
11. Boettiger CA, Kelley EA, Mitchell JM, D'Esposito M, Fields HL (2009) Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav93:291-299.
12. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA95:9608-9613.
13. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PAJr, O'Brien CP, Berrettini WH, Grice DE (2003) A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet13:169-173.
14. Ducat E, Ray B, Bart G, Umemura Y, Varon J, Ho A, Kreek MJ (in press) Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict Biol. doi: [Epub ahead of print].
15. Ducci F, Goldman D (2008) Genetic approaches to addiction: genes and alcohol. Addiction103:1414-1428.
16. Ehlers CL, Lind PA, Wilhelmsen KC (2008) Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. BMC Med Genet9:35.
17. Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT, Tanabe J, Du YP, Hutchison KE (2008a) Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. Neuropsychopharmacology33:1391-1401.
18. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE (2008b) Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res32:1113-1123.
19. Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W (2001) Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet105:114-119.
20. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA293:1617-1625.
21. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res31:555-563.
22. Gelernter J, Kranzler H, Cubells J (1999) Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry4:476-483.
23. Gelernter J, Kranzler HR (2009) Genetics of alcohol dependence. Hum Genet126:91-99.
24. Gianoulakis C (2009) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem9:999-1015.
25. Goldman D, Oroszi G, O'Malley S, Anton R (2005) COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol15:56-64.
26. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR (2007) Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics17:1031-1038.
27. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet118B:60-65.
28. Hines LM, Ray L, Hutchison K, Tabakoff B (2005) Alcoholism: the dissection for endophenotypes. Dialogues Clin Neurosci7:153-163.
29. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM (2000) Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet9:2895-2908.
30. Kendler KS, Prescott CA, Neale MC, Pedersen NL (1997) Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. Arch Gen Psychiatry54:178-184.
31. Kim SG (2009) Gender differences in the genetic risk for alcohol dependence-the results of a pharmacogenetic study in Korean alcoholics. Nihon Arukoru Yakubutsu Igakkai Zasshi44:680-685.
32. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl)201:611-618.
33. Koob G, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry164:1149-1159.
34. Kranzler HR, Edenberg HJ (2010) Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des16:2141-2148.
35. Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D (1998) Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol Clin Exp Res22:1359-1362.
36. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol29:350-357.
37. Kreek MJ (1996) Opiates, opioids and addiction. Mol Psychiatry1:232-254.
38. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem103:77-87.
39. Kuehn BM (2009) Findings on alcohol dependence point to promising avenues for targeted therapies. JAMA301:1643-1645.
40. Lesko LJ, Woodcock J (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov3:763-769.
41. Lesko LJ, Zineh I (2010) DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics11:507-512.
42. Levran O, Awolesi O, Linzy S, Adelson M, Kreek MJ (2011) Haplotype block structure of the genomic region of the mu opioid receptor gene. J Hum Genet56:147-155.
43. Luo X, Kranzler HR, Zhao H, Gelernter J (2003) Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet120B:97-108.
44. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA (2009) Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA106:10847-10852.
45. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res30:1288-1296.
46. Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK (2004) A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol Psychiatry9:99-108.
47. Miranda R, Ray L, Justus A, Meyerson LA, Knopik VS, McGeary J, Monti PM (2010) Initial evidence of an association between OPRM1 and adolescent alcohol misuse. Alcohol Clin Exp Res34:112-122.
48. Nielsen DA, Hamon S, Yuferov V, Jackson C, Ho A, Ott J, Kreek MJ (2010) Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts. Hum Genet127:639-649.
49. Nielsen DA, Yuferov V, Hamon S, Jackson C, Ho A, Ott J, Kreek MJ (2009) Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology34:867-873.
50. O'Brien CP (2008) Prospects for a genomic approach to the treatment of alcoholism. Arch Gen Psychiatry65:132-133.
51. Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W (2009) Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol14:328-337.
52. Oroszi G, Anton RF, O'Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res33:383-393.
53. Oroszi G, Goldman D (2004) Alcoholism: genes and mechanisms. Pharmacogenomics5:1037-1048.
54. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology28:1546-1552.
55. Oslin DW, Berrettini WH, O'Brien CP (2006) Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol11:397-403.
56. Plomin R, Haworth CM, Davis OS (2009) Common disorders are quantitative traits. Nat Rev Genet10:872-878.
57. Pratt WM, Davidson D (2009) Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol44:358-365.
58. Prescott CA, Kendler KS (1999) Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry156:34-40.
59. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry16:809-817.
60. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL (2009) Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA106:10811-10816.
61. Ray LA (2011) Stress-induced and cue-induced craving for alcohol in heavy drinkers: preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. Alcohol Clin Exp Res35:166-174.
62. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res28:1789-1795.
63. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry64:1069-1077.
64. Ray LA, Hutchison KE, Ashenhurst JR, Morrow AL (2010a) Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the ASP40 allele of the OPRM1 gene: a pilot investigation. Alcohol Clin Exp Res34:1479-1487.
65. Ray LA, Hutchison KE, Tartter M (2010b) Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des16:2149-2158.
66. Ray LA, Mackillop J, Monti PM (2010c) Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst Use Misuse45:1742-1765.
67. Ray LA, Miranda RJr, Tidey JW, McGeary JE, MacKillop J, Gwaltney CJ, Rohsenow DJ, Swift RM, Monti PM (2010d) Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. J Abnorm Psychol119:115-125.
68. Ray LA, Oslin DW (2009) Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend105:256-258.
69. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev18:247-291.
70. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M (2002) A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry7:224-228.
71. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C, Leyton M (2011) The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res35:1134-1141.
72. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G (2002) Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat19:459-460.
73. Tan EC, Tan CH, Karupathivan U, Yap EP (2003) Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport14:569-572.
74. Tate SK, Goldstein DB (2004) Will tomorrow's medicines work for everyone?Nat Genet36(11 Suppl):S34-S42.
75. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda RJr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res32:58-66.
76. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M (1999) Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet88:458-461.
77. Vallender EJ, Ruedi-Bettschen D, Miller GM, Platt DM (2010) A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug Alcohol Depend109:252-256.
78. van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van Breukelen GJ (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res31:1-10.
79. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology26:106-114.
80. Way BM, Taylor SE, Eisenberger NI (2009) Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc Natl Acad Sci USA106:15079-15084.
81. Wiers RW, Rinck M, Dictus M, van den Wildenberg E (2009) Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1G-allele. Genes Brain Behav8:101-106.
82. Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L, Goate A, Bucholz K, Schuckit M, Nurnberger JJr, Tischfield J, Kuperman S, Porjesz B, Begleiter H, Foroud T, Edenberg HJ (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry11:1016-1024.
83. Xuei X, Flury-Wetherill L, Bierut L, Dick D, Nurnberger JJr, Foroud T, Edenberg HJ (2007) The opioid system in alcohol and drug dependence: family-based association study. Am J Med Genet B Neuropsychiatr Genet144B:877-884.
84. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem280:32618-32624.